Toth LN, et al. - An inquiry was performed of the prevalence and features of non-small cell lung cancers (NSCLC) with isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations. During this research, 800 lung cancer samples were successfully sequenced for somatic mutations on the Ion Torrent PGM with the 50 gene AmpliSeq Cancer Hotspot Panel v2 on the Ion Torrent PGM (318 chip) from May 2013 – March 2017. A smoking history was present in all patients' tumors had adenocarcinoma histology and all patients. Findings disclosed that 88% of patient's tumors had a co-existing KRAS mutation and 6 of 8 were diagnosed at >70 years of age. Stage IV disease was noted in 5 patients and 3 presented with stage I. After comparing with a cohort of KRAS mutated NSCL with a history of smoking, IDH mutated cases appeared to be considerably older but exhibited similar rates of advanced stage disease and gender distribution.